+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05544019

Phase 1 Study of Oral SGR-1505 for Treatment of Mature B-Cell Cancers

Led by Schrödinger, Inc. · Updated on 2026-02-13

98

Participants Needed

36

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying SGR-1505, an oral MALT1 inhibitor, in adults with relapsed or refractory mature B-cell lymphomas. The study aims to evaluate the safety, tolerability, and pharmacological properties of SGR-1505 while determining the maximum tolerated or recommended dose. Exploratory groups will further assess early anti-tumor activity and safety, including combinations with other cancer drugs like BTK and BCL-2 inhibitors in specific B-cell cancers. Participants will receive SGR-1505 orally across up to nine different dose levels using two dosing schedules. Patients will be assigned to dose groups following an accelerated titration design that shifts to a traditional dose escalation method. The study is open-label and non-randomized, focusing on careful dose increases to find the optimal dosing for further research. During the study, participants will be closely monitored for adverse events, dose limiting toxicities, and treatment effects over up to two years. Researchers will track drug levels in the blood, tumor response rates, and disease control measures. Safety assessments, pharmacokinetics, and pharmacodynamics evaluations will occur throughout, with ongoing observation to understand the drugs impact and tolerability in this patient population.

CONDITIONS

Brief Title

Study of SGR-1505 in Mature B-Cell Neoplasms

Research Team

S

Study Physician

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here